The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 971-977

  Louandre, Christophe ^a   Marcq, Ingrid ^b   Bouhlal, Hicham ^b   Lachaier, Emma ^a,b   Godin, Corinne ^a,b   Saidak, Zuzana ^a   François, Catherine ^b   Chatelain, Denis ^a   Debuysscher, Véronique ^b   Barbare, Jean Claude ^b   Chauffert, Bruno ^b   Galmiche, Antoine ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Ferroptosis; Hepatocellular carcinoma; Rb; Sorafenib

Indexed keywords

RETINOBLASTOMA PROTEIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BALB/C NUDE MOUSE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FERROPTOSIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; RNA INTERFERENCE; RNA STABILITY; TUMOR REGRESSION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; LIVER NEOPLASMS; METABOLISM; MITOCHONDRION; NECROSIS; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; FEMALE; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; NECROSIS; NIACINAMIDE; OXIDATIVE STRESS; PHENYLUREA COMPOUNDS; REACTIVE OXYGEN SPECIES; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919432703     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.014     Document Type: Article

References (28)

1. Knudsen E.S., Gopal P., Singal A.G. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am. J. Pathol 2014, 184:574-583.
2. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med 2008, 359:378-390.
3. Ezzoukhry Z., Louandre C., Trécherel E., Godin C., Chauffert B., Dupont S., et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int. J. Cancer 2012, 131:2961-2969.
4. Godin C., Dupont S., Ezzoukhry Z., Louandre C., Chatelain D., Henaut L., et al. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. Anticancer Res 2013, 33:1415-1420.
5. Galmiche A., Chauffert B., Barbare J.C. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett 2014, 346:159-162.
6. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
7. Galmiche A., Ezzoukhry Z., François C., Louandre C., Sabbagh C., Nguyen-Khac E., et al. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol. Cancer Res 2010, 8:1116-1125.
8. Louandre C., Ezzoukhry Z., Godin C., Barbare J.C., Mazière J.C., Chauffert B., et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer 2013, 133:1732-1742.
9. Lachaier E., Louandre C., Godin C., Saidak Z., Baert M., Diouf M., et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumours. Anticancer Res 2014, 34(11):6417-6422.
10. Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012, 149:1060-1072.
11. Yang W.S., Sriramaratnam R., Welsch M.E., Shimada K., Skouta R., Viswanathan V.S., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014, 156:317-331.
12. Dolma S., Lessnick S.L., Hahn W.C., Stockwell B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003, 3:285-296.
13. Knudsen E.S., Knudsen K.E. Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 2008, 8:714-724.
14. Laurent-Puig P., Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006, 25:3778-3786.
15. Anwar S.L., Krech T., Hasemeier B., Schipper E., Schweitzer N., Vogel A., et al. Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma. J. Pathol 2014, 233:392-401.
16. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet 2012, 44:694-698.
17. Munakata T., Liang Y., Kim S., McGivern D., Huibregtse J., Nomoto A., et al. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 2007, 3:1335-1347.
18. Mayhew C.N., Carter S.L., Fox S.R., Sexton C.R., Reed C.A., Srinivasan S.V., et al. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 2007, 133:976-984.
19. Viatour P., Ehmer U., Saddic L.A., Dorrell C., Andersen J.B., Lin C., et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J. Exp. Med 2011, 208:1963-1976.
20. Valencia A., Sapp E., Kimm J.S., McClory H., Reeves P.B., Alexander J., et al. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Hum. Mol. Genet 2013, 22:1112-1131.
21. Zheng C., Fang Y., Tong W., Li G., Wu H., Zhou W., et al. Synthesis and biological evaluation of novel tetrahydro-β-carboline derivatives as antitumor growth and metastasis agents through inhibiting the transforming growth factor-β signaling pathway. J. Med. Chem 2014, 57:600-612.
22. Shimizu S., Takehara T., Hikita H., Kodama T., Tsunematsu H., Miyagi T., et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int. J. Cancer 2012, 131:548-557.
23. Yagoda N., von Rechenberg M., Zaganjor E., Bauer A.J., Yang W.S., Fridman D.J., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007, 447:864-868.
24. Li Y., Trush M.A. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem. Biophys. Res. Commun 1998, 253:295-299.
25. Vanden Berghe T., Linkermann A., Jouan-Lanhouet S., Walczak H., Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol 2014, 15:135-147.
26. Dixon S.J., Patel D.N., Welsch M., Skouta R., Lee E.D., Hayano M., et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014, 3. e02523.
27. Coriat R., Nicco C., Chéreau C., Mir O., Alexandre J., Ropert S., et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol. Cancer Ther 2012, 11:2284-2293.
28. Shen Y.C., Ou D.L., Hsu C., Lin K.L., Chang C.Y., Lin C.Y., et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br. J. Cancer 2013, 108:72-81.